tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Nov 11;10(11):1905.
doi: 10.3390/vaccines10111905.
Fulminant Type 1 Diabetes Mellitus after SARS-CoV-2 Vaccination: A Case Report
Rong Lin[SUP] 1 2 [/SUP], Yu-Wei Lin[SUP] 3 [/SUP], Mei-Hsiu Chen[SUP] 2 4 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been used worldwide to control the coronavirus disease pandemic. However, several adverse effects have been reported following vaccination. Therefore, further research on the adverse effects in individuals predisposed to life-threatening conditions is needed. Herein, we present a 39-year-old woman without any systemic disease who developed fulminant type 1 diabetes mellitus (T1DM) (low glycohemoglobin levels, despite hyperglycemia and diabetic ketoacidosis (DKA)) following SARS-CoV-2 vaccination. The patient was initially misdiagnosed as having fresh type 2 diabetes mellitus after the first episode of DKA, which was resolved by short-term insulin therapy and treated with oral anti-diabetic agents after the DKA was resolved. This made her develop a second episode of DKA shortly after treatment. The course and presentation of our case are noteworthy for alerting clinicians to vaccine-related fulminant T1DM.
Keywords: SARS-CoV-2; SARS-CoV-2 vaccines; diabetes mellitus; fulminant; type 1.
. 2022 Nov 11;10(11):1905.
doi: 10.3390/vaccines10111905.
Fulminant Type 1 Diabetes Mellitus after SARS-CoV-2 Vaccination: A Case Report
Rong Lin[SUP] 1 2 [/SUP], Yu-Wei Lin[SUP] 3 [/SUP], Mei-Hsiu Chen[SUP] 2 4 [/SUP]
Affiliations
- PMID: 36423001
- DOI: 10.3390/vaccines10111905
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been used worldwide to control the coronavirus disease pandemic. However, several adverse effects have been reported following vaccination. Therefore, further research on the adverse effects in individuals predisposed to life-threatening conditions is needed. Herein, we present a 39-year-old woman without any systemic disease who developed fulminant type 1 diabetes mellitus (T1DM) (low glycohemoglobin levels, despite hyperglycemia and diabetic ketoacidosis (DKA)) following SARS-CoV-2 vaccination. The patient was initially misdiagnosed as having fresh type 2 diabetes mellitus after the first episode of DKA, which was resolved by short-term insulin therapy and treated with oral anti-diabetic agents after the DKA was resolved. This made her develop a second episode of DKA shortly after treatment. The course and presentation of our case are noteworthy for alerting clinicians to vaccine-related fulminant T1DM.
Keywords: SARS-CoV-2; SARS-CoV-2 vaccines; diabetes mellitus; fulminant; type 1.